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Abstract
The scope of this short review is to summarise the knowledge gleaned from the fate of drugs transported by
albumin upon contact with the target cancer cell or cells in inflamed tissues. The authors expertise covers
covalently bound drugs and their cellular uptake and release from albumin. This review therefore aims to deduce
what will happen to drugs such as insulin detemir which is considered to bind non-covalently to albumin and may
have a fate similar to fatty acids transported by albumin.
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Introduction
Insulin detemir was developed as a long acting drug to
achieve a continuous and steady blood level of insulin
rather than the peaks achieved with postprandial injec-
tions of conventional insulin. The molecule was modi-
fied by eliminating Thr 30 and adding a C14 fatty acid
(myristic acid) by a chemically very stable amide bond
to the epsilon amine of Lys 29 on the B chain of human
insulin [Figure 1]. The reason for the long duration of
action of insulin detemir of about 20 hrs compared to
12- 16 hrs for Neutral Protamine Hagedorn (NPH) insu-
lin is considered to be its binding to human serum albu-
min (HSA) to be released either at the insulin receptor
or in circulation [1]. The mechanisms of its binding and
even more so of its release are, however, not very clear
and the author of this short review will try to critically
evaluate the literature available on the subject in view of
the properties of albumin loaded with either fatty acids
or covalently bound drugs and its cellular uptake.
Albumin as drug carrier
Albumin is the major protein in blood plasma, its blood
levels are tightly regulated because of its importance for
homeostasis [2]. One of its functions is the transport of
physiological non or poorly water soluble molecules like
fatty acids, steroids and drugs. These are bound to dis-
tinct hydrophobic pockets in the albumin molecule,
which has a very rigid and stable three dimensional
structure due to 17 S-S bonds. In addition albumin con-
tains very few aromatic amino acids but many amino
acids with functional groups like amino and carboxyl
groups, these contribute to stabilising the blood pH. In
addition to greatly increasing its stability against sol-
vents, denaturing agents and heat - an unusual property
for a protein of 66 kDa molecular weight - these func-
tional groups make albumin amenable to chemically link
drugs. The body is, however, very sensitive to the struc-
ture of albumin and rapidly eliminates any molecules
which have not retained the native structure of albumin
[3]. Therefore only albumin-drug carriers with a molar
loading ratio of on average 1.4 moles of drug per mole
of albumin are physiologically stable and attain half-lives
similar to native albumin [4].
Cellular uptake of albumin
Under conditions of cellular stress, as in growing
tumour tissue, albumin is taken up by cells as a source
of amino acids and energy [5]. This was shown with
albumin covalently labelled with a radiolabel or a fluor-
escent dye, such as aminofluorescein, at a molar ratio of
approximately one. The fate of the protein can thus be
traced in cellular systems, but also in vivo in experimen-
tal animals and, with the fluorescent conjugate, also in
patients.
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by endocytosis into the lysosomal compartment of
cells, where it is degraded. The exact mechanism lead-
ing to endocytosis, i.e. which membrane receptor is
responsible and if the process is indeed receptor
mediated is not yet entirely elucidated. In endothelia a
gp60 protein, albondin, binds albumin and is a shuttle
enabling transcytosis of albumin into the underlying
tissue [6]. As of now there is no evidence that this
protein is expressed on tumour cells and it is not very
likely that it is the receptor leading to lysosomal tar-
geting of albumin. The protein SPARC (secreted pro-
tein, acidic and rich in cysteine) also binds native
albumin and antibodies directed against gp60 [6].
SPARC has therefore been suggested to be involved in
cellular albumin uptake [7]. SPARC is a protein found
expressed at higher levels in tumour tissue than in
healthy organs [7]. There is no direct experimental
proof of SPARC-mediated cellular albumin uptake.
Our own data have shown albumin binding proteins to
be expressed on various human tumour cell lines
derived from solid tumours and on leukemic cells [8].
Whether these proteins indeed mediate albumin
uptake has not been shown. Clathrin heavy chain si-
RNA used to inhibit clathrin-mediated endocytosis did
not change the uptake of labelled albumin into tumour
cells, but inhibited the uptake of transferrin which was
used as positive control. Hypertonic sucrose in the
media very effectively inhibited uptake of both, labelled
albumin and transferrin, but also of dextran (V. Pohl
personal communication Ph.D. thesis). Together these
data point to a possible fluid-phase uptake of albumin,
because hypertonic conditions inhibit both, clathrin
and fluid-phase endocytosis; for the latter dextran is a
marker [9]. Since albumin is such a ubiquitous mole-
cule any experimental setting to show the mechanism
of its uptake pathway is very difficult to perform.
In experimental animals bearing solid tumours radio-
actively-or fluorescently labelled albumin was taken up
into tumours specifically [3]. The same specific uptake
of albumin into inflamed joints of mice in the collagen
induced arthritis model as into tumour tissue was seen
[10], emphasizing the similarity of physiological pro-
cesses in inflammation and tumour growth, such as an
increased catabolism of proteins [5].
Clinical studies
In a clinical study testing aminofluorescein-labelled
albumin as a diagnostic agent for fluorescence guided
brain surgery, we could show that all glioblastoma
patients included in the study accumulated fluorescence
and thereby albumin into the tumour and not in the
normal brain, the oedema or necrosis. The fluorescence
of the tumour facilitated brain surgery [11].
The pharmacokinetics performed on these patients
showed a terminal plasma half-life of 12.8 days [12],
which is similar to the half-life reported for native albu-
min of 19 days [2], emphasizing the importance of a care-
ful loading procedure of albumin with drug or tag.
Higher loading ratios of drug to albumin had been shown
to lead to accumulation in the liver, rather than in the
tumour. Such modified albumins are rapidly eliminated
by the reticulo-endothelial system of the liver [3].
Clinical studies with methotrexate covalently linked by
an amide bond to a lysine in human serum albumin
showed moderate efficiency against solid tumours in
phase I and phase II clinical studies [13,14]. Solid
tumours such as renal cell carcinoma, which are usually
not treated with methotrexate, were sensitive to this
drug linked to albumin. Also here, a long plasma half-
life of the drug protein conjugate was found, probably
the reason for the observed effect together with the spe-
cific enrichment in tumour tissue. In in vitro experi-
ments the amide bond was found to be extremely stable
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Figure 1 Insulin detemir. Thr at position 30 in the B chain in human insulin was cleaved off and myristic acid covalently attached to Lys 29 in
the B chain to enable albumin (HSA) binding.
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ate linked to lysine as the final metabolite after proteoly-
sis [15].
Insulin detemir and albumin binding
Also in this molecule an amide bond links the fatty acid
myristate to a lysine at position 29 on the B chain of
insulin resulting in a longer half-life of insulin detemir
than insulin in blood. The reason for this is postulated
to be binding of the fatty acid to albumin, because of
fatty acid binding sites on albumin. These are discrete
regions on the molecule accommodating long chain
fatty acids, which are essential and have chain lengths
between C16 and C20 either saturated or with up to 4
double bonds. Medium chain fatty acids (C6-C14) are
normally not transported by albumin, because they are
much more water soluble and are normally not found
outside cells [2]. Binding affinities of such medium
chain fatty acids are much lower than of the long chain
fatty acids for which 2 strong and 4 weaker binding
sites on albumin have been found. Medium chain fatty
acids are excluded from these primary strong binding
sites. Initial binding is a rapid ionic interaction of the
carboxyl group with albumin leading to a hydrophobic
interaction of the fatty acid chain with the loops of the
protein. Non charged ligands bind less tightly, this
would also be true for insulin-detemir, because the car-
boxyl group of its fatty acid is masked in an amide
bond, and therefore no extra charge compared to insulin
is added. Insulin itself binds only weakly to albumin.
The glucose lowering potency of insulin detemir is
much lower than of human insulin, the reason being
that binding of the former to the insulin receptor is
much weaker. This has been shown recently by Soren-
sen who compared the displacement of radioactively
labelled insulin from the receptor by insulin and insulin
detemir [16]. The authors also show that this low bind-
ing affinity for the insulin receptor can be further
decreased by adding fatty acid free albumin to the incu-
bation. They needed approximately four fold higher
insulin detemir concentrations for half maximal displa-
cement of radioactive insulin from the insulin receptor,
but not of insulin, if albumin was increased from 0.1%
to 1% in the cell medium at insulin detemir concentra-
tions around 10
-7 M. It is, however, not clear if indeed
albumin binding of insulin detemir is the reason for this
observation, because a 0.1% albumin solution is 15 μM
and at 1% 150 μM, i.e. 150 or 1500 times more concen-
trated than the insulin detemir added. In addition the
albumin was essentially fat-free, therefore expected to
bind at least 3 moles of ligand per mole albumin [2].
The albumin binding studies performed by the same
group showed displacement of insulin detemir by fatty
acids with chain lengths of C12 and C16. At an insulin
detemir to albumin ratio of one, 50% is displaced. Insulin
detemir is therefore considered to bind to the medium to
long fatty acid binding site [17]. The balance between
albumin binding of insulin detemir and its displacement
by long chain fatty acids in blood is difficult to estimate
from these in vitro assays, since here fatty acid free albu-
min was used for a clear experimental set-up, but this
species does not occur in vivo. The further fate of insulin
detemir bound to albumin and the question whether it
might be internalised is an educated guess. Fatty acids
are „liberated” from albumin by various fatty acid trans-
porters or fatty acid binding proteins, which however do
not transport fatty acid esters or triglycerides [18]. Insu-
lin detemir therefore is probably not a substrate for these
proteins. If insulin detemir were bound covalently or
more tightly than fatty acid, which is not the case, uptake
of the albumin bound drug into lysosomes might occur.
Insulin would then not be active anymore because pro-
teases would degrade the carrier and the ligand. This
might happen to a small extent and might contribute to
the lower potency of insulin detemir compared to insulin.
How likely such a cellular uptake is, however, difficult to
deduce from the data available.
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